[경제]SK Bioscience public offering stock fever… the first day of 14,800 billion won

[앵커]

In the first half of the year, sk Bioscience, which is regarded as one of the main targets for public offerings, started to offer public offerings.

On the first day of subscription, more than 14 trillion won was gathered, and the amount of margin on the first day of SK Biopharm and Big Hit, which drove a sensation of subscriptions last year, was significantly exceeded.

Reporter Park Byung-han reports.

[기자]

The first day of subscription to SK Bioscience.

Securities companies are busy with people who have signed up for public offerings.

Customers who visited a securities company to open an account to sign up for a public offering stock were regretted because it was late.

[증권회사 직원 : 혹시 고객님 공모주 때문에 계좌 만드시는 건가요? 공모주 계좌 개설은 어제까지 만들어야 청약이 가능했어요.]

The public offering price for SK Bioscience is KRW 65,000, and subscriptions to general investors are received at six securities companies including NH Investment & Securities and Korea Investment & Securities for two days.

The amount allocated to individual investors is 57,375,500 shares, which is 25% of the total public offering, and half of the newly introduced equally allocated amount is 2.86 million,8750 shares.

The minimum margin for 10 weeks of subscription stock is 325,000 won.

According to the equal distribution method, you can secure one share by subscribing the minimum subscription amount of 10 weeks and inserting a margin of 325,000 won, but if the number of subscribers exceeds 2.86 million, it will be allocated by lottery.

Margins received at 6 securities companies at around 4 pm on the first day were estimated at KRW 1.48 trillion, and the average subscription competition rate is estimated to be about 83:1.

This margin exceeds the record for the first day of the first day of 8.6 trillion won by Big Hit Entertainment, which heated up the IPO market for public offerings last year.

However, the margin on the first day of Kakao Games was less than 16.4 trillion won.

SK Biosciences has signed contracts with global companies such as AstraZeneca to produce Corona 19 vaccines, and will be listed on the stock market on the 18th.

Investors are keenly interested in whether or not to record a double ceiling on the listing date.

Starting with SK Bioscience, expecting IPOs are waiting.

[장순일 / NH투자증권 부장 : 올해 안에 상장 예정인 SK IT, 카카오뱅크, LG에너지솔루션 등 다수 종목이 있으니 여기에 관심을 가져주시면 됩니다.]

This year’s public offering market is expected to be hotter than ever, as interest from small investors has increased through the equal distribution of public offering stocks.

This is YTN Park Byung-han.

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]